Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
申请人:Asselin Magda
公开号:US20070027160A1
公开(公告)日:2007-02-01
The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT
1A
binding agents, particularly as 5-HT
1A
receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction.
Piperazine-piperidine antagonists and agonists of the 5-HT1A receptor
申请人:Wyeth LLC
公开号:US07671056B2
公开(公告)日:2010-03-02
The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I′):
wherein R1-R16, Ra, Rb, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I′).
PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR
申请人:Wyeth
公开号:EP1888559A2
公开(公告)日:2008-02-20
US7671056B2
申请人:——
公开号:US7671056B2
公开(公告)日:2010-03-02
[EN] PIPERAZINE-PIPERIDINE ANTAGONISTS AND AGONISTS OF THE 5-HT1A RECEPTOR<br/>[FR] ANTAGONISTES ET AGONISTES PIPERAZINO-PIPERIDINIQUES DU RECEPTEUR 5-HT1A
申请人:WYETH CORP
公开号:WO2006135839A2
公开(公告)日:2006-12-21
[EN] The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agon f its. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. [FR] La présente invention concerne de nouveaux composés pipérazino-pipéridiniques. Ils conviennent comme agents se liant à 5-HT1A, et particulièrement comme antagonistes et agonistes du récepteur 5-HT1A. Ces composés conviennent pour le traitement de troubles du système nerveux central tels que les troubles de la cognition, les troubles à anxiété, la dépression et les dysfonctions sexuelles.